Standard of care (SOC) changes when therapies are not just approved, but integrated into major guidelines, reimbursed, and operationally feasible at scale. In 2026, the most transformative changes cluster in oncology, metabolic disease (obesity/diabetes), mental health, rare genetic disorders, and Alzheimer's disease, driven by recent FDA approvals, major guideline updates, and strong phase 3 data.

Key Therapy Domains and Drivers

1. Oncology

a. Menin inhibitors in acute myeloid leukemia (AML)

• Dana‑Farber highlights menin inhibitors as ""monumental"" for the ~40% of AML cases driven by KMT2A rearrangements or NPM1 mutations, with two drugs recently approved and being combined with other therapies [1].

• These agents move from late‑line rescue towards earlier‑line regimens in high‑risk AML, reshaping SOC for genetically defined subsets.

b. Novel RAS inhibitors for pancreatic and other RAS‑mutant cancers

• A phase 3 trial of a novel RAS inhibitor in RAS‑mutant pancreatic cancer shows promising survival benefits; Dana‑Farber notes potential to ""transform"" treatment of one of the deadliest cancers [1].

• If ongoing trials confirm benefit, RAS inhibitors are likely to become core SOC components for KRAS‑mutant pancreatic and possibly other solid tumors.

c. Personalized cancer vaccines

• Neoantigen‑based mRNA vaccines for melanoma and kidney cancer are in clinical trials and highlighted as a major 2026 advance [1].

• By training each patient's immune system against tumor‑specific antigens, these vaccines are poised to join (or replace) standard adjuvant immunotherapy in select cancers once pivotal data mature.

d. Radioligand therapy (RLT)

• Radioligand therapy has moved into earlier‑line treatment for metastatic prostate cancer and is being explored in other tumors [1].

• Because it couples radiotherapy to molecular targeting, RLT is likely to become SOC for certain metastatic settings, particularly where systemic radiation previously had limited precision.

e. Next‑generation cell therapies

• Dana‑Farber describes a wave of ""next‑gen"" CAR T‑cell, NK‑cell, and tumor‑infiltrating lymphocyte (TIL) therapies, with ongoing trials moving them into earlier lines and broader indications [1].

• As manufacturing and toxicity management improve, expect cell therapies to expand from narrow, refractory blood cancers into earlier‑line hematologic use and possibly select solid tumors, altering SOC sequencing.

2. Metabolic Disease: Obesity and Type 2 Diabetes

a. GLP‑1 and dual GIP/GLP‑1 agonists as core obesity treatment

• The 2026 ADA Standards of Care in Overweight and Obesity elevate high‑efficacy agents—semaglutide and tirzepatide—as central pharmacologic treatments, with explicit comorbidity‑driven algorithms (prediabetes, T2D, ASCVD, HFpEF, MASH, OSA, osteoarthritis) [2].

• Tirzepatide, a dual GIP/GLP‑1 RA, is recommended or strongly favored across many comorbidity scenarios, reflecting superior weight‑loss and cardiometabolic benefits [2].

• These drugs move obesity care from ""lifestyle only"" to chronic pharmacologic management, effectively redefining SOC for patients with obesity and major comorbidities.

b. Integrating obesity pharmacotherapy and diabetes care

• The 2026 ADA diabetes standards embed GLP‑1 RAs and dual GIP/GLP‑1 RAs into glycemic and cardiovascular‑risk algorithms, especially for patients with MASLD/MASH, ASCVD, CKD, and HFpEF [3].

• Obesity‑focused agents are now first‑line or early‑line for many high‑risk patients, displacing older agents with less benefit and consolidating a new SOC of weight‑centric diabetes management.

c. Weekly basal insulin (Awiqli – insulin icodec‑abae)

• FDA's 2026 novel drug approvals list Awiqli, a once‑weekly basal insulin for adults with type 2 diabetes [4].

• Weekly insulin meaningfully lowers treatment burden and may improve adherence, making it a likely successor to daily basal insulin analogs as SOC once payers and guidelines adapt.

3. Mental Health

a. Rapid‑acting psychedelics and neuromodulation

• A 2026 mental‑health advances review highlights:

• Psilocybin (COMP360) for treatment‑resistant depression (TRD), with phase 3 data showing substantial, durable symptom reduction after a single supervised dose; FDA submission is anticipated [5].

• MM120 (LSD‑based therapy) for generalized anxiety, with phase 2b results (65% response, 48% remission) and Breakthrough Therapy designation, moving into phase 3 [5].

• Vagus nerve stimulation (VNS), with long‑term data showing sustained benefit and up to 20% full remission at two years in severe depression [5].

• These therapies are likely to become SOC options for TRD and severe anxiety where SSRIs/SNRIs, psychotherapy, and even ECT fall short, creating a new interventional tier rather than incremental tweaks to existing drugs.

b. Precision psychiatry

• The same review flags pharmacogenomics‑guided prescribing and AI‑supported precision psychiatry as tools to reduce trial‑and‑error medication selection [5].

• As payers and large systems adopt pharmacogenomic panels and decision‑support tools, SOC in depression, anxiety, and bipolar disorder will increasingly incorporate genotype‑informed and data‑driven treatment selection.

4. Rare Genetic and Metabolic Diseases

a. Gene‑editing therapies for sickle cell disease (SCD)

• Cleveland Clinic reports on renizgamglogene autogedtemcel (reni‑cel): in the RUBY trial, 27 of 28 severe SCD patients had no painful crises post‑treatment, with substantial increases in fetal hemoglobin and total hemoglobin and no graft rejection (autologous cells) [6].

• Although still experimental in 2026, this one‑time CRISPR‑based therapy has the characteristics of a functional cure. Combined with the FDA's new framework for small‑population gene‑therapy approvals (Reuters notes reliance on smaller trials and real‑world evidence) [7], reni‑cel or similar products are poised to replace chronic transfusions and hydroxyurea as SOC for eligible severe SCD patients over the next few years.

b. Other rare disorders in the 2026 approvals list

• Several newly approved therapies are disease‑modifying for rare metabolic or lysosomal diseases:

• Avlayah (tividenofusp alfa‑eknm) for Hunter syndrome,

• Loargys (pegzilarginase‑nbln) for Arginase 1 Deficiency,

• Zycubo (copper histidinate) for Menkes disease,

• Yuviwel (navepegritide) for achondroplasia growth promotion [4].

• Given the lack of effective alternatives, these agents will quickly become SOC for their indications, though patient numbers are small.

5. Alzheimer's Disease and Cognitive Decline

a. Disease‑modifying anti‑amyloid therapies

• Leqembi (lecanemab) and Kisunla (donanemab)—approved in 2023 and 2024—are already shifting SOC for early Alzheimer's by slowing cognitive decline. A 2026 forecast by BrightFocus notes:

• At‑home injectable forms of lecanemab have been approved, with an FDA decision in May 2026 on whether starter doses can also be initiated at home [8].

• This could move anti‑amyloid therapy from infusion centers to home‑based care, expanding real‑world SOC reach.

• AHEAD study testing lecanemab in pre‑symptomatic, high‑risk individuals may, if positive, push SOC toward pre‑symptomatic intervention [8].

b. Emerging oral therapies and device‑based interventions

• Oral candidates like blarcamesine and ALZ‑801 (tramiprostate), in late‑stage development, could broaden SOC beyond infusions if approved [8].

• Non‑drug interventions (brain stimulation, 40 Hz light/sound ""flicker"" therapy, focused ultrasound to open the blood–brain barrier) are being studied as adjuncts, with early evidence of slowed decline or enhanced delivery of other therapies [8]. These may become SOC adjuncts in specialized centers.

Counterarguments and Constraints

• Access and cost: Gene therapies and some oncology agents carry prices in the hundreds of thousands to millions of dollars per patient; payer coverage and health‑system budgets will gate how quickly they become practical SOC.

• Safety: Anti‑amyloid therapies have ARIA risk; cell and gene therapies involve serious conditioning/toxicity; psychedelics require intensive monitoring and specialized infrastructure.

• Infrastructure: At‑home biologics, advanced cell therapies, and psychedelic sessions all require new operational models, staff training, and regulatory guardrails.

• Evidence maturity: Some promising therapies (e.g., CRISPR SCD, oral Alzheimer's agents, certain cancer vaccines) are not yet fully approved or still have limited long‑term safety data.

Implications

1. Therapeutic targeting and personalization become the default SOC model—driven by genetic, biomarker, and phenotypic profiling.

2. Care pathways will be reorganized around infusion centers, at‑home biologic administration, and interventional mental‑health suites.

3. Payers will increasingly adopt outcomes‑based contracting and strict eligibility criteria for high‑cost therapies.

4. Clinical guidelines (ADA, oncology societies, Alzheimer's organizations) will continue rapid iteration as 2026 data mature, making guideline surveillance a core strategic function.